Table 1.
Demographic characteristics of patients and controls.
| IRD | CTRL | |
|---|---|---|
| n | 237 | 232 |
| Age mean [CI 95%] | 57 (56-59) | 57 [56-58] |
| M:F | 73/164 | 71/161 |
| Diagnosis of IRD n (%) | 237 (100) | 0 (0) |
| RA n (%) | 86 (36.3) | - |
| SpA n (%) | 71 (30.0) | - |
| - axSpA | 14 (5.9) | - |
| - PsA | 48 (20.3) | - |
| - Other | 9 (3.8) | - |
| CTD n (%) | 62 (26.2) | - |
| - UCTD | 7 (2.9) | - |
| - SSc | 21 (8.9) | - |
| - SLE | 20 (8.4) | - |
| - pSS | 3 (1.3) | - |
| - IM | 6 (2.5) | - |
| - MCTD | 1 (0.4) | - |
| - APS | 4 (1.7) | - |
| Vsc n (%) | 14 (5.9) | – |
| AI n (%) | 4 (1.7) | - |
| Treatment | – | |
| csDMARD n (%) | 154(64.9) | – |
| - MTX | 94 (39.7) | – |
| - HCQ | 14 (5.9) | – |
| - MMF | 16 (6.8) | – |
| - AZA | 16 (6.8) | - |
| - SSZ | 9 (3.8) | - |
| - LEF | 2 (0.8) | - |
| - Colchicine | 3 (1.3) | - |
| bDMARD and tsDMARD n (%) | 118 (49.8) | - |
| - TNFi | 49 (20.7) | - |
| - ABA | 15 (6.3) | - |
| - UST | 7 (3.0) | - |
| - IL-17i | 14 (5.9) | - |
| - IL-6i | 12 (5.0) | - |
| - IL-1i | 2 (0.8) | - |
| - RTX | 4 (1.7) | - |
| - BEL | 1 (0.4) | - |
| - PDE4i | 1 (0.4) | - |
| - JAKi | 18 (7.6) | - |
IRD, Immune rheumatic disease; IQR, Interquartile range; RA, Rheumatoid Arthritis; SpA, Spondyloarthritis; axSpA, axial Spondyloarthritis; PsA, Psoriatic Arthritis; CTD, Connective tissue diseases; UCTD, Undifferentiated Connective Tissue Disease; SSc, Systemic Sclerosis; SLE, Systemic Lupus Erythematosus; pSS, primary Sjögren Syndrome; IM, Inflammatory Myositis; MCTD, Mixed Connective Tissue Disease; APS, Antiphospholipid Syndrome; Vsc, Vasculitides; AI, Autoinflammatory Diseases; csDMARD, conventional synthetic Disease-Modifying Antirheumatic Drug; MTX, Methotrexate; HCQ, Hydroxychloroquine; MMF, Mycophenolate Mofetil; AZA, Azathioprine; SSZ, sulfasalazine; LEF, Leflunomide; bDMARD, biological Disease-Modifying Antirheumatic Drug; tsDMARD, targeted synthetic Disease-Modifying Antirheumatic Drug; TNFi, TNF alpha-inhibitors; ABA, Abatacept; UST, Ustekinumab; IL-17i, IL-17-inhibitors; IL-6i, IL-6-inhibitors; IL-1i, IL-1-inhibitors; RTX, Rituximab; BEL, belimumab; PDE4i, phosphodiesterase 4-inhibitors; JAKi, Janus kinase-inhibitors.